Evaluation of practice patterns in the treatment of atrial fibrillation among the commercially insured

References

• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001;285:2370-5
   PubMed Web of Science ®Google Scholar
• Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995;155:469-73
   PubMed Web of Science ®Google Scholar
• Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation – executive summary. Circulation 2006;114:e257-354
   PubMed Web of Science ®Google Scholar
• Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guidelines): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:104-23
   PubMed Web of Science ®Google Scholar
• Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:e269-367
   PubMed Web of Science ®Google Scholar
• Morillo C, Verma A, Kuck KH, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation (RAAFT 2): a randomized trial [abstract]. Heart Rhythm 2012;9:1580
   Google Scholar
• Allen LaPointe NM, Governale L, Watkins J, et al. Outpatient use of anticoagulants, rate-controlling drugs, and antiarrhythmic drugs for atrial fibrillation. Am Heart J 2007;154:893-8
   PubMed Web of Science ®Google Scholar
• Pilote L, Eisenberg MJ, Essebag V, et al. Temporal trends in medication use and outcomes in atrial fibrillation. Can J Cardiol 2013;29:1241-8
   Google Scholar
• Kashyap A, Li C. Trends in utilization of management strategies for newly diagnosed atrial fibrillation patients in the United States: 1999–2008. J Pharm Pract 2012;25:151-9
   PubMedGoogle Scholar
• Reiffel JA, Kowey PR, Myerburg R, et al. Practice patterns among United States cardiologists for managing adults with atrial fibrillation (from the AFFECTS Registry). Am J Cardiol 2010;105:1122-9
   PubMed Web of Science ®Google Scholar
• Shah RU, Freeman JV, Shilane D, et al. Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation. J Am Coll Cardiol 2012;59:143-9
   PubMed Web of Science ®Google Scholar
• Cappato R, Calkins H, Chen S-A, et al. Worldwide survey on methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005;111:1100-5
   PubMed Web of Science ®Google Scholar
• Weerasooriya R, Khairy P, Litalien J, et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol 2011;57:160-6
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8
   PubMed Web of Science ®Google Scholar
• Stroke Prevention in Atrial Fibrillation III. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633-8
   PubMed Web of Science ®Google Scholar
• European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62
   PubMed Web of Science ®Google Scholar
• Adam SS, McDuffie JR, Ortel TL, et al. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med 2012;157:796-807
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67
   PubMed Web of Science ®Google Scholar
• You JJ, Singer DE, Howard PA, et al. Anthrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based practice guidelines. Chest 2012;141(2 Suppl):e531S-75S
   PubMed Web of Science ®Google Scholar
• Kirley K, Qato DM, Kornfield R, et al. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012;5:615-21
   PubMed Web of Science ®Google Scholar
• Piccini JP, Mi X, DeWald TA, et al. Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. Heart Rhythm 2012;9:1403-8
   PubMed Web of Science ®Google Scholar
• Jones M, McEwan P, Morgan CL, et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005;91:472-7
   PubMed Web of Science ®Google Scholar
• Ruigómez A, Johansson S, Wallander MA, et al. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol 2002;55:358-63
   PubMed Web of Science ®Google Scholar
• Lakshminarayan K, Solid CA, Collins AJ, et al. Atrial fibrillation and stroke in the general Medicare population: a 10-year perspective. Stroke 2006;37:1969-74
   PubMed Web of Science ®Google Scholar
• Hodgkinson JA, Taylor CJ, Hobbs DR. Treatment pathways for patients with atrial fibrillation. Int J Clin Pract 2012;66:44-52
   PubMed Web of Science ®Google Scholar
• Chiang C-E, Naditch-Brûlé L, Murin J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice. Insight from the Real-Life Global Survey Evaluating Patients With Atrial Fibrillation International Registry. Circ Arrhythm Electrophysiol 2012;5:632-9
   PubMed Web of Science ®Google Scholar
• Raji MA, Lowery M, Lin YL, et al. National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries. Ann Pharmacother 2013;47:35-42
   PubMed Web of Science ®Google Scholar
• Darkow T, Vanderplas AM, Lew KH, et al. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Curr Med Res Opin 2005;21:1583-94
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality. Comparative effectiveness of radiofrequency catheter ablation for atrial fibrillation. AHRQ Publication No. 09-EHC015-EF. July 2009
   Google Scholar
• Bradley BC, Perdue KS, Tisdel KA, et al. Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center. Am J Cardiol 2000;85:568-72
   PubMed Web of Science ®Google Scholar
• Cullen MW, Kim S, Piccini JP Sr, et al. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes 2013;6:461-9
   PubMed Web of Science ®Google Scholar
• Van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: a systemic review and metaregression. Chest 2006;129:1155-66
   PubMed Web of Science ®Google Scholar
• Lane DA, Lip GYH. Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors. Stroke 2008;39:7-9
   PubMed Web of Science ®Google Scholar
• Nieuwlaat R, Capucci A, Lip GY, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006;27:3018-126
   PubMed Web of Science ®Google Scholar
• Lip GY, Agnelli G, Thach AA, et al. Oral anticoagulation in atrial fibrillation: a pan-European patient survey. Eur J Intern Med 2007;18:202-8
   PubMed Web of Science ®Google Scholar
• Devereaux PJ, Anderson DR, Gardner MJ, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 2001;323:1218-22
   PubMed Web of Science ®Google Scholar
• Wasser T, Wu B, Ycas J, et al. Comparison of commercial insurance databases to census data for age, gender and geographic region in the United States. Presented at: International Society for Pharmacoeconomics and Outcomes Research 18th Annual International Meeting, 18–22 May 2013, New Orleans, LA, USA
   Google Scholar